AbbVie Receives Clearance from FDA on Once-Daily Chrohn’s Disease Pill
Marks seventh approval for Rinvoq in the pharmaceutical field.
AbbVie, a pharmaceutical organization, has received FDA approval for Rinvoq as a daily pill treatment for Crohn’s disease in adults. With this authorization, the medication has officially been approved seven time across rheumatology, dermatology, and gastroenterology, where it is shown in both ulcerative colitis and Crohn's disease.
"AbbVie recognizes the need for more treatment options for Crohn's disease that can help address both rapid relief of symptoms along with the visible reduction of intestinal lining damage," said Thomas Hudson, senior vice president, research and development, chief scientific officer, AbbVie. "We're pleased that RINVOQ may provide this relief and is now available to treat Crohn's disease."
The Misinformation Maze: Navigating Public Health in the Digital Age
March 11th 2025Jennifer Butler, chief commercial officer of Pleio, discusses misinformation's threat to public health, where patients are turning for trustworthy health information, the industry's pivot to peer-to-patient strategies to educate patients, and more.
Navigating Distrust: Pharma in the Age of Social Media
February 18th 2025Ian Baer, Founder and CEO of Sooth, discusses how the growing distrust in social media will impact industry marketing strategies and the relationships between pharmaceutical companies and the patients they aim to serve. He also explains dark social, how to combat misinformation, closing the trust gap, and more.
